A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

Study Summary

This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.

Conditions

Achondroplasia

Interventions / Drugs

BMN 111

View on ClinicalTrials.gov ↗

Sponsor

BMRN

BioMarin Pharmaceutical

Rare Disease

D36/100

Study Details

Enrollment30 participants

Primary Completion—

Lead SponsorBioMarin Pharmaceutical

Data Retrieved2026-04-11 02:55:23.531389+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.